During the London leg of Charles River’s Cell and Gene Summit tour, Ramin Baghizade, Global Commercial Head of Gene Therapy at Charles River, announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids.
Charles River has stated that the new addition to the product and service suite further streamlines their solution to the challenges associated with plasmid sourcing in cell and gene therapies. Echoed by Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions:
“We are thrilled to announce this addition to our product offering. Our LVV packaging plasmids allow us to further support advanced therapy programs and most importantly, help expedite the delivery of safe, effective therapies to those who need them most.”
Identifying production challenges, including capacity bottlenecks, timeline pressures and process development optimization impacting increased cost, complexity and lead times, this new off-the-shelf packaging plasmids address obstacles related to critical plasmid DNA starting materials.
With immediate availability, the LVV packaging plasmids offer an alternative, reportedly with ‘reduced development costs and simplified supply chains that streamline and secure lentiviral vector production’.
“Charles River’s LVV packaging plasmids offer researchers and manufacturers a high-quality, reliable tool to support their LVV viral vectors production. The new plasmids will be a valuable resource to develop new treatments for a wide range of programs in preclinical and clinical development with the continuity of supply for commercial use,” Andrew Frazer, Associate Director, Scientific Solutions, added.
The news of the launch compliments established offerings, included under their plasmid DNA CDMO services.
In an exclusive interview with Phacilitate, Ramin Baghizade alluded to future announcements in the pipeline within the lentiviral space. Watch the interview above to find out more.